Further studies are needed to dissect the implication of NLRP3 and the risk of developing T2D in patients with RA (Ruscitti et al., 2019) and to highlight the potential application of NLRP3-targeted therapies for these diseases. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.